Anti-p53 (Phospho-Ser392) Monoclonal Antibody (Clone:FP3.2 [FPS392])

Figure-1: Immunohistochemistry staining of Wild-type p53 expressed in human trophoblast (paraffin-embedded sections). A - anti-p53 (total) B - anti-p53 (phospho Ser392) Note that some of total p53 positive nuclei are also FP3.2 (phospho p53) positive.

Anti-p53 (Phospho-Ser392) Monoclonal Antibody (Clone:FP3.2 [FPS392])

Roll over image to zoom in

Figure-1: Immunohistochemistry staining of Wild-type p53 expressed in human trophoblast (paraffin-embedded sections). A - anti-p53 (total) B - anti-p53 (phospho Ser392) Note that some of total p53 positive nuclei are also FP3.2 (phospho p53) positive.

Figure-2: Western blotting analysis of phosphorylated human p53 using mouse monoclonal antibody FP3.2 (purified) in T47D cell line, which expresses p53. A) Phosphorylated p53 detected in T47D cell line. B) Absence of phosphorylated signal of p53 in dephosphorylated T47 cells (pretreated with calf intestinal alkaline phosphatase).

Product code: 30-1325

Clone name :	FP3.2 [FPS392]
Clonality :	Monoclonal
Application :	WB
Reactivity :	Human

Shipping Info:

For estimated delivery dates, please contact us at [email protected]

Download TDS MSDS

Write a review for this product on BioCompare

Get $20 gift card from Amazon

Shipping Info:

For estimated delivery dates, please contact us at [email protected]

Download TDS MSDS

Format :	Purified
Amount :	0.1 mg
Isotype :	Mouse IgG1
Purification :	Purified by protein-A affinity chromatography
Storage condition :	Store at 2-8°C. Do not freeze.


Gene :	TP53
Gene ID :	7157
Uniprot ID :	P04637
Alternative Name :	TP53, P53
Immunogen Information :	KLH-conjugated phosphopeptide RHKKLMFKTEGPDS[P]D, corresponding to amino acids 378-393 of human p53.

The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nukleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization.

Immunohistochemistry (paraffin sections): Standard ABC technique (DAB+), pretreatment: high temperature antigen retrieval (microwave, pressure cooker) in 10 mM citrate buffer pH 6.0 or 1 mM EDTA-NaOH buffer pH 8.0, recommended dilution: 10 μg/ml, incubation: 1 hour at RT; or overnight at 4°C, positive tissue: breast carcinoma with high level of wild-type p53.
Western blotting: recommended dilution: 1 μg/ml.

For Research Use Only. Not for use in diagnostic/therapeutics procedures.

Subcellular location:	Cytoplasm
Post transnational modification:	Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9.
Tissue Specificity:	Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.
BioGrid:	113010. 1093 interactions.